hCTLA-4 Mouse Model
| Strain Name | hCTLA-4 Mouse Model |
|---|---|
| Strain Background | C57BL/6N |
Applications
-
Anti-CTLA-4 drug evaluation: Test ipilimumab-like mAbs and next-gen checkpoint inhibitors
-
Checkpoint blockade studies: Model CTLA-4–mediated T cell inhibition and release by ICI
-
Treg biology: Study CTLA-4–dependent immune tolerance and bystander suppression
-
Combo IO regimens: Validate CTLA-4 + PD-1 dual blockade in syngeneic tumor models
Strain Description
The hCTLA-4 Mouse Model carries a targeted knock-in of the human CTLA-4 gene at the endogenous mouse locus. It replaces the murine Ctla4 coding sequence while preserving native promoters and regulatory elements. Therefore, it ensures physiological expression of functional human CTLA-4 protein in the same cell types where the endogenous gene is normally expressed, predominantly activated T cells and regulatory T cells. As a result, this human CTLA-4 knock-in mouse mirrors human CTLA-4–B7 (CD80/CD86) high-affinity interactions more closely than wild-type strains.
In this hCTLA-4 model, CTLA-4 competes with CD28 for B7 ligands on antigen-presenting cells. Its higher affinity for CD80/CD86 allows CTLA-4 to outcompete CD28 and block co-stimulatory signaling. Furthermore, CTLA-4 recruits SHP-2 and PP2A phosphatases via its cytoplasmic tail, dampening TCR proximal signaling. On regulatory T cells, constitutive CTLA-4 expression drives B7 endocytosis and degradation, creating localized immune suppression.
This humanized CTLA-4 model allows therapeutics to engage authentic human CTLA-4 epitopes. For example, you can test antagonistic anti-CTLA-4 monoclonal antibodies such as ipilimumab analogs. Similarly, it supports evaluation of CTLA-4–targeted bispecific formats or combination regimens with anti-PD-1. Consequently, the hCTLA-4 Mouse Model provides a translational platform for checkpoint blockade efficacy, safety, and combination immunotherapy that conventional models cannot replicate.
FAQ
Game-changing benefits？
While competitors highlight germline efficiency gains, shorter timelines and enhanced 3Rs animal welfare benefits for their technologies, these are merely incremental improvements over traditional approaches. In sharp contrast, our proprietary technology delivers fully pure, homogeneous lineages—every single cell of the mice is derived exclusively from totipotent ES cells, with guaranteed 100% germline transmission efficiency. To experience these unparalleled benefits firsthand, enquire about your custom mouse model project with us or order embryos for in-house validation at your facility.
How much for a project assessment?
•Free initial design proposal with zero obligations.
•Request a free quote!
Who owns the mouse lP? Do l need a licence from Mingceler?
All model generation projects of Mingceler operate under a fee-for-service framework.
IP Ownership: All intellectual property rights related to custom mouse models, including derived organs, tissues, cells, and biological materials, are the sole and exclusive property of the Client.
Third-Party Transfer Permission: The Client may independently decide to retain, utilize, or commercialize their custom models project materials (e.g., targeting vectors, ES cells, mouse lines) without the need for prior consent from Mingceler.
Licensing Exemption: The Client has full autonomy over all uses of the custom models or their derivatives, including but not limited to commercialization, distribution to third parties, and publication involving model data. No written license from Mingceler is required for such uses.